Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Xylem, Inc. (XYL) Price & Performance

Abbott LaboratoriesTrade
Xylem, Inc.Trade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Xylem, Inc. — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while Xylem, Inc. trades at $123.07 (market cap $28.76B). The key difference: Abbott Laboratories is far larger — about 6.5× Xylem, Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.

ABTXYL
Market Cap
$187.95B$28.76B
Sector
HealthIndustrials
52-Week High
$136.62$152.95
52-Week Low
$82.57$106.34
Enterprise Value
$214.96B$30.54B
Dividend Yield
2.32%1.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

Xylem, Inc.

Xylem (XYL) trades at $121.87, up 0.56% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company's fundamentals show robust revenue growth, expanding margins, and healthy cash flow, supported by strategic acquisitions like Cornell Pump and Roper Pump to bolster its industrial water technology presence. Analyst consensus is mixed but leans positive, with a $150.43 price target implying significant upside.

Outlook remains favorable due to secular demand in water infrastructure and AI-driven data centers, though risks include execution on acquisitions and economic sensitivity. The stock offers growth potential from margin expansion and digital water solutions, but investors should monitor integration challenges and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Xylem, Inc.

Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.

Read more on XYL